Test code: 8568
Effective update from 02/11/2020
Due to the evolution and current knowledge about SARS-Cov-2 virus, serological tests used in the management of this disease should allow healthcare professionals to evaluate not only quantifiable variations in antibody levels over time but also their ability to provide immunity.
Synlab's medical indication is to perform tests designed to detect antibodies against 2 antigens of the Spike protein: S1/RBD and S2. Otherwise we would be ignoring the presence of supposedly blocking and protective antibodies. Tests directed to other targets only indicate contact with the virus but not if anti-S antibodies have been generated, which are the important regarding protection and vaccination.
For this reason, we are changing the technique used in the serological analysis of SARS- Cov-2 virus IgG. This change means a modification in both units and reference values of the result, which cannot be correlated with previous results of patient samples analized by different techniques.
Method: Chemiluminescent Microparticle Immuno Assay (CMIA)
Negative : Index less than 1.40
Positive : Index equal or greater than 1.40
Version of Test: 58
Negative : Less than 12.0 AU/mL
Grey zone: 12.0 - 15.0 AU/mL
Positive : Equal or greater than 15.0 AU/mL
Version of Test: 59
Find the record of the test by clicking here